Cargando…
Overcoming delivery barriers in immunotherapy for glioblastoma
Glioblastoma is one of the deadliest forms of primary adult tumors, with median survival of 14.6 months post-diagnosis despite aggressive standard of care treatment. This grim prognosis for glioblastoma patients has changed little in the past two decades, necessitating novel treatment modalities. On...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164566/ https://www.ncbi.nlm.nih.gov/pubmed/34053034 http://dx.doi.org/10.1007/s13346-021-01008-2 |